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ABSTRACT
Introduction: Little is known about the
pharmacokinetics of amikacin during
continuous renal replacement therapy.
Methods: This prospective observational study
included patients admitted to an academic
medical center who received amikacin therapy
while on continuous veno-venous hemodialysis
(CVVHD) and had at least two serum sample
concentrations measured after first-dose
administration. First-order pharmacokinetic
parameters, patient characteristics, and
CVVHD parameters were recorded.
Results: Fifteen patients were included in the
analysis. The median (interquartile range) dose
of amikacin and dialysate flow rate, based
on adjusted body weight, were 14.1 mg/kg
(11.7–17.3 mg/kg) and 23.9 mL/kg/h
(19.0–29.5 mL/kg/h), respectively. This
corresponded with a median Cmax of 28.5 lg/
mL (20.9–39.0 lg/mL). There was a significant
correlation between clearance and dialytic dose
(for every 1 L/h increase in dialysate flow rate,
clearance rate increased by 23.6 mL/min
[95% confidence interval 1.7–45.4 mL/min;
P = 0.037]).
Conclusion: The results of this study suggest
that amikacin dose and interval should be
individualized for each patient on CVVHD
based on first-dose pharmacokinetic
assessment.
Keywords: Amikacin; Continuous renal
replacement therapy; Pharmacokinetics
INTRODUCTION
Infection is common among critically ill
patients and is associated with considerable
morbidity and mortality [1, 2]. In a large,
1-day, cross-sectional study of intensive care
unit (ICU) patients, 51% were considered
infected, while 71% were receiving antibiotics
[3]. Among ICU patients infected with
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Gram-negative bacteria, the incidence of
resistance continues to rise [4]. Optimal and
timely antibiotic treatment of critically ill,
infected patients is paramount to maximizing
survival [5, 6]. Given the epidemiological trends
of Gram-negative pathogens and the increased
incidence of resistance, many treatment
guidelines recommend the use of empiric dual
Gram-negative coverage, which frequently
includes the use of an aminoglycoside [7–9].
The Surviving Sepsis Campaign guidelines
further recommend that adequate initial doses
of antibiotics should be given to ensure that
serum concentrations are attained to maximize
efficacy and minimize toxicity; nevertheless,
these antibiotic doses are infrequently evidence
based in critically ill patients [10].
Infected patients may develop a spectrum of
biologic response, ranging from systemic
inflammatory response syndrome to septic
shock and death. Acute renal failure occurs
proportionally to the extent of the biologic
response to infection, ranging from 19% in
patients with sepsis to 51% in patients with
septic shock [11, 12]. Among critically ill
patients with acute kidney injury requiring
renal replacement therapy, continuous renal
replacement therapy (CRRT) is frequently
used [13].
Understanding the pharmacokinetic (PK)
characteristics of aminoglycoside during CRRT
warrants further investigation, given the
importance of attaining adequate antibiotic
serum concentrations and the increasing need
for this class of antimicrobials in critically ill
patients. Among the aminoglycosides, amikacin
is useful for gentamicin-resistant Gram-negative
pathogen infections or as empiric treatment in
institutions with a local epidemiological pattern
suggesting the need to use this medication [14].
Despite its crucial role in therapy, a survey of
the literature reveals a relative paucity of
amikacin PK data among critically ill patients.
In particular, there are fewer than 50 reports of
amikacin PK parameters during CRRT [15–22].
Despite the availability of these reports, their
clinical applicability is limited by a number of
factors.
CRRT generally removes toxins and drugs
through either diffusive and/or convective
processes. Drug clearance for a particular
medication may be affected by the mode of
CRRT used, inter- and intra-patient variation in
dialytic dose, and institutional variations in
CRRT machines and filters. The majority of the
reports on amikacin PK characteristics during
CRRT were from a period of time where CRRT
was performed with relatively lower dialysate
or replacement fluid flow rates (0.6–1.2 L/h)
compared to current CRRT prescriptions
(2–4 L/h), or with hemofilters no longer used
in clinical practice [15–18]. In addition, few of
the reports provided the characteristics of the
dialysis machine, the mode of CRRT, and filter
details. Lastly, only one report describes the
PK characteristics of amikacin in patients
undergoing continuous veno-venous
hemodialysis (CVVHD) [16]. There are several
reports of amikacin PK with novel CRRT
parameters; however, they comprise fewer
than 30 cases in total. Furthermore, some
novel reports of amikacin PK characteristics
involved five or fewer patients in their analysis
[21, 22] and one report focused on patients with
burn injury [20], which may have confounding
PK implications. Given the paucity of data and
the continued need for broad-spectrum
antibiotics targeting Gram-negative pathogens
in an era of newer CRRT machines and filters
with drastically higher flow rates, the PK
characteristics of amikacin warrant further
investigation. As such, we performed a
prospective observational study of patients
who received amikacin therapy while on
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CVVHD to further characterize the PK
parameters of the medication.
MATERIALS AND METHODS
This was a prospective observational study of a
convenient sample of patients admitted to a
medical ICU of a tertiary care academic medical
center, who received amikacin therapy while on
CVVHD. Patient characteristics, amikacin
dosing, and CVVHD parameters, including
machine, filter, effluent, and dialysate flow
rates, were collected from an intensive care
database that was approved by the Cleveland
Clinic Institutional Review Board (IRB). The
database was approved by the local IRB as part
of a registry for the evaluation of intensive
care pharmacotherapy-related outcomes. The
current study was performed by querying the
existing data within the registry with no
additional information collected through chart
review or patient contact. A waiver of informed
consent was granted by the local IRB.
The decision to administer amikacin and the
prescribed dose/frequency were determined by
the primary ICU service, and not prescribed
by the study protocol. Patients with at least
two amikacin serum sample concentrations
measured after the first dose of amikacin were
included in the study. Serum amikacin
concentration measurements were drawn as
part of routine patient monitoring and levels
were generally determined more than 8 h apart.
Amikacin levels were measured by our local
institutional laboratory using the Advia 1200
system (Siemens Medical Solutions, Malvern,
PA, United States) chemistry analyzer with an
enzyme immunoassay technique. The assay
measures total amikacin level and has a
quantification range of 2.5–50 lg/mL, with a
detection limit of 1 lg/mL and a coefficient of
variation of approximately 10%. First-order
pharmacokinetics with a single compartment
were assumed and estimations of the peak
concentration (Cmax), volume of distribution
(Vd), elimination constant (Kel), clearance (Cl),
and terminal half-life (t) were performed.
The equations used to calculate the various
PK criteria can be found in Table 1. All
calculations were performed assuming all
amikacin removal was from CRRT clearance
alone. For all calculations, the ideal body weight
(IBW) was used unless patients were more
than 30% above their IBW. If patients were
more than 30% above their IBW, then a dosing
weight (DW) was used [DW = IBW ? 0.4 (actual
weight in kg - IBW)] [14].
The decision to administer CRRT was made
as per recommendations from the nephrology
ICU consult service. Selection of the machine
for dialysis and filter choice were based upon
chance equipment availability at the time of
CVVHD initiation. However, in accordance
with our local practice, CVVHD was performed
using a Prismaflex System (Gambro,
Lakewood, CO, USA) or System OneTM dialysis
system (NxStage, Lawrence, MA, USA) with
either a polyacrylonitrile [(AN69)Prismaflex
M100, 0.9 m2 membrane surface area] or a
polysulfone hemofilter (NxStage Cartridge
Table 1 Pharmacokineticformulas
Pharmacokinetic parameter Equation
Elimination constant (kel), h
-1 ln(C2/C1)/(t2 - t1)
Half-life (t), h 0.693/kel
Projected peak (Cmax), lg/mL C1

ln(ekel DtÞ
Volume of distribution (Vd), L D/Cmax
Clearance (Cl), mL/min Vd 9 kel
Dt time between ﬁrst concentration drawn and 30 min
after infusion completion, C1 ﬁrst measured concentration,
C2 second measured concentration, D dose, t1 time when
ﬁrst concentration was drawn, t2 time when second
concentration was drawn
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Express, 1.5 m2 membrane surface area),
respectively. The CVVHD parameters,
including blood flow rate, dialysate flow rate,
ultrafiltration rate, or the need for filter
anticoagulation, were determined by the
nephrology ICU consult service based on
individual patient needs. In general, an
ultrafiltration rate ranging from 50 to
150 mL/h was added to the CVVHD dialysate
rate to optimize machine running time and
facilitate volume removal (as determined by the
nephrology and primary ICU services). Because
this ultrafiltration rate was relatively small
compared to the dialysate rate (about 5%), the
dialysis modality was still considered CVVHD,
as opposed to continuous veno-venous
hemodiafiltration, or CVVHDF.
Statistical Analysis
Continuous data are presented as median
(interquartile range, IQR), unless otherwise
specified. Pearson correlation was utilized to
assess the relationship between amikacin PK
parameters and CVVHD characteristics. Linear
regression was performed to evaluate the
relationship between the dose administered
and the projected peak amikacin
concentration, as well as the relationship
between dialysate flow rate and amikacin
clearance. Statistics were computed using SPSS
software, version 15.0 (SPSS Inc., Chicago,
Illinois), and a P value \0.05 was considered
statistically significant.
RESULTS
Fifteen patients were included in the analysis.
Their median (IQR) age was 56 (45–67) years
with a median (IQR) weight of 84 (64–117) kg.
Only two of the patients had end-stage renal
disease, while the remainder required CRRT due
to acute kidney injury. Patients had minimal
residual renal function with a median (IQR)
urine output of 10 (0–52) mL in the 24 h after
amikacin administration. The patients were all
critically ill with a median (IQR) APACHE II
score of 25 (22–30), with 14 (93%) requiring
mechanical ventilation.
Four patients (26.7%) were dialyzed using
the NxStage machine with NxStageCartridge
Express polysulfone filter, while 11 (73.3%)
patients were dialyzed using the Prismaflex
machine with the M100 acrylonitrile filter.
The individual dialysis characteristics are
shown in Table 2. The median (IQR) age of
the dialysis filter at the time of amikacin
administration was 10 (3–28) h. Minimal
interruption in continuous dialysis was
observed during the amikacin sampling
period, with a median (IQR) interruption
time of 15 (0–300) min. The median
(IQR) dialysate, weight-adjusted dialysate,
ultrafiltration, and blood flow rates were
2,000 (1,825–2,450) mL/h, 23.9 (19.0–29.5)
mL/kg/h, 50 (50–100) mL/h, and 200
(150–200) mL/min, respectively.
The median (IQR) dose of amikacin, based
on adjusted body weight (DW), was 14.1
(11.7–17.3) mg/kg. The individual amikacin
dose and PK parameters are presented in
Table 3. The amikacin dose administered
corresponded with a median (IQR) projected
Cmax of 28.5 (20.9–39.0) lg/mL. The Vd, Cl,
and t were 0.39 (0.28–0.57) L/kg, 36.7
(22.8–44.5) mL/min, and 12.7 (8.7–16.7) h,
respectively. Correlation analyses found a
significant correlation between clearance and
dialytic dose. Using simple linear regression, for
every 1 L/h increase in dialysate flow rate, the
clearance rate increased by 23.6 mL/min (95%
CI 1.7–45.4 mL/min; P = 0.037). In addition,
220 Infect Dis Ther (2013) 2:217–226
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the dose administered corresponded
significantly with the projected peak amikacin
serum concentration (Fig. 1).
DISCUSSION
In this study of a convenient sample of patients
who received amikacin while on CVVHD, a
significant positive correlation was found
between amikacin clearance rate and dialysate
flow rates. All patients in this study were treated
with CVVHD utilizing synthetic dialysis filters
and relatively high dialysate flow rates. The
dialytic dose used in this study was
complementary to those described by a recent
survey of the management of critically ill
patients with acute renal failure [23]. Despite
the correlation between amikacin clearance and
dialysate flow rates, the wide range of projected
Cmax and t seen in this study indicate that the
exact amikacin dosing regimen cannot be
accurately predicted based on the dialytic dose
or other factors available at the bedside. As such,
it would appear to be most appropriate to
perform first-dose PK calculations to determine
the appropriate dosing regimen for each patient.
Among many Gram-negative species across
the world, the minimum inhibitory
concentration to inhibit 90% of bacterial
isolates (MIC90) for amikacin is 8 lg/mL [24];
optimal antibacterial activity is achieved when
the amikacin Cmax is eight to ten times greater
than the MIC. Based on the projected PK from
this analysis, to achieve a peak of 64 lg/mL
(8-times an MIC of 8 lg/mL), a projected dose of
about 25 mg/kg (based on DW) is needed. This
is consistent with a recent report by Taccone
and colleagues, who studied PK parameters after











1 Prismaﬂex 200 2,500 50 40.0
2 Prismaﬂex 150 2,000 100 23.5
3 Prismaﬂex 160 2,350 50 9.0
4 Prismaﬂex 200 3,000 100 10.0
5 NxStage 150 2,800 50 3.0
6 Prismaﬂex 200 2,000 150 43.0
7 Prismaﬂex 150 2,400 50 0.5
8 Prismaﬂex 150 2,000 50 1.5
9 NxStage 150 1,200 50 0.5
10 Prismaﬂex 200 1,800 50 28.0
11 NxStage 200 1,600 50 8.0
12 Prismaﬂex 200 2,500 100 3.8
13 NxStage 200 2,000 100 22.5
14 Prismaﬂex 160 1,850 50 47.0
15 Prismaﬂex 200 1,800 50 10.0
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a dose of 25 mg/kg of total body weight was
administered to patients with severe sepsis and
septic shock [25]. Among patients with renal
dysfunction (defined as creatinine Cl \50 mL/
min) in this study, a dose of 25 mg/kg achieved
a Cmax, Vd, Cl, and t of 71.5 lg/mL, 0.42 L/kg,
1.29 mL/min/kg, and 7.6 h, respectively.
Remarkable similarities were seen between the
Vd in the study by Taccone and colleagues [25]
and that in the present study. In a subgroup of
the patients from the Taccone study undergoing
CVVHDF, the t and Cl were 6.5 h and 1.26 mL/
kg/min (about 5.3 L/h for a 70-kg patient),
respectively [19]. These values are drastically
higher than those found in our study, which
could be explained by the considerably higher
dialytic dose used in that study (median
dialysate and ultrafiltration rates of 29 mL/
kg/h and 33 mL/kg/h, respectively, for an
approximate total CRRT dose of 62 mL/kg/h).
Similarly, in a recent study of five patients
undergoing CVVHDF, D’Arcy and colleagues
[21] demonstrated an amikacin t and Cl of
6.7 h and 56.6 mL/min, respectively. This study













t (h) Time to serum
level <5 lg/mL
1 1,300 12.4 28.5 0.43 61.0 8.6 21.7
2 750 11.7 37.7 0.31 37.7 6.1 17.8
3 1,000 12.9 89.5 0.23 12.4 16.7 69.7
4 1,000 12.2 19.8 0.61 36.7 15.9 31.6
5 1,250 14.7 27.6 0.53 95.1 5.5 13.6
6 1,250 21.1 60.1 0.35 18.9 12.7 45.6
7 1,000 10.4 21.0 0.50 44.5 12.4 25.6
8 750 10.5 24.3 0.43 20.1 17.8 40.5
9 540 10.8 17.4 0.62 22.8 15.8 28.4
10 1,000 14.2 31.3 0.45 37.2 9.9 26.3
11 830 14.6 20.9 0.70 22.8 20.2 41.6
12 1,500 17.3 19.5 0.89 43.1 20.6 40.5
13 1,250 17.7 57.6 0.31 48.9 5.1 18.1
14 1,000 18.3 39.0 0.68 30.1 14.2 42.2
15 800 15.3 31.4 0.49 33.1 8.9 23.5
* Per adjusted body weight
Fig. 1 Association between Cmax and dose
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utilized an ultrafiltration rate of 2 L/h and a
dialysate rate of 1–2 L/h.
In contrast to the studies listed above, other
studies have found considerably lower clearance
rates than our study. Armendariz and colleagues
presented a case report of a patient undergoing
CVVH and found that total body clearance
of amikacin was 10.5 mL/min and CVVH
clearance was 10.11 mL/min [15]. This
approximated the hemofiltration rate to be
10 mL/min. They found an elimination
constant of 0.023 h-1, which corresponds to a
t of 29.7 h. This study found clearance rates
from CRRT to be similar to those reported for
patients in renal failure without the use of
dialysis. The median clearance rate of amikacin
in our study (36.7 mL/min) was drastically
higher than that reported by Armendariz and
colleagues. Of note, the dialysate flow rates
described in the current report are
approximately twice those reported by
Armendariz and colleagues [15]. Given the
high sieving coefficient of 0.93 for amikacin, it
is conceivable that the flow rates during CRRT
would dictate the amount of drug removal [26].
This premise is supported by other studies that
utilized higher dialysate or ultrafiltration rates
with subsequent findings of higher rates of
amikacin clearance. Roberts and colleagues
reported data from five patients on CVVH,
with average flow rates of 19.2 mL/min (1.2 L/
h) and found a mean hemofiltration clearance
rate of 16.4 mL/min [18]. Taken together, it
appears that across studies, the overall dialytic
dose may affect amikacin clearance. This is
consistent with the findings of our current
study, which suggest that dialytic dose
correlates with amikacin clearance. However,
there are still many other factors that would
ultimately determine the PK profile of
amikacin. These may include inter-patient
variability in non-dialytic measures, such as
volume status, non-renal intrinsic clearance,
the age of the filter, and interruptions to
CVVHD.
Of interest, a study by Cotera and colleagues
that evaluated amikacin clearance in five
patients with acute oliguric renal failure
undergoing CVVHD found that the amikacin
clearance rates were only 3.57 and 4.18 mL/min
with 1 and 2 L/h dialysate rates, respectively
[16]. Even though the 2 L/h dialysate rate was
only slightly lower than that reported in the
current study, the authors noted drastically
lower clearance rates than in our study. This
could potentially be explained by the type of
hemodialyzer membrane utilized. Notably, all
the previous studies discussed and the current
study utilized synthetic hemodialyzer
membranes composed of either acrylonitrile or
polysulfone. In contrast, the study by Cotera
and colleagues [16] utilized a cuprofen
(cellulose) dialysis membrane. A decrease in
drug clearance with the use of cellulose dialysis
membranes compared to polysulfone has been
well documented [27–30]. This may partially be
explained by significant adsorption of
aminoglycosides to synthetic membranes,
which may contribute to an increase in overall
clearance [31–33]. As such, all PK evaluations of
aminoglycosides should readily report the
type of filter, its age at the time of drug
administration, and any potential filter
changes during the PK sampling period.
Our study has several limitations. Similar to
previous studies, the external validity of this
study may be limited, given that all patients
received CVVHD using either the Prismaflex or
NxStage machine. Of note, only 4 of the
15 patients received dialysis via the Nxstage
machine; therefore, the data presented here
may be more applicable to patients receiving
dialysis via the Prismaflex machine. Likewise,
the considerable institutional differences in the
Infect Dis Ther (2013) 2:217–226 223
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practice of CRRT, including the mode, filter
material, and dialysate and ultrafiltration rates,
may limit the external applicability of this
study. In addition, the methods used in the
current study do not allow for differentiation
between extracorporeal clearance and intrinsic
clearance. The patients in our study had
minimal residual kidney function, but in
patients with some remaining renal function,
clearance of amikacin may be higher. Lastly, the
PK profiles evaluated in this study were
obtained after the first dose of amikacin.
Therefore, no conclusions could be made
regarding the PK characteristics of amikacin
beyond the initial dose. The strengths of our
study include the largest number of patients
evaluated to date and explicit notation of
dialytic characteristics (which could affect PK
parameters) that reflect more current practices
with CRRT.
CONCLUSION
In conclusion, our study found a significant
correlation between dialysate flow rate and
amikacin clearance. Institutions should
evaluate their usual dialytic practice to
examine the flow rates routinely prescribed,
which may provide a good starting estimate
for amikacin clearance. However, given the
considerable inter-individual variability
observed in this study, an a priori prediction
of PK parameters and optimal amikacin dose
to be administered to patients on CVVHD may
be challenging. Therefore, determination of
the optimal dose of amikacin and dosing
interval should be achieved by serum
concentration monitoring and subsequent
dose adjustments. Furthermore, the exact
amikacin dosing regimen needs to be
individualized based on the presumed MIC of
the pathogen, site of infection, and other host
factors. Due to the large number of potential
confounders, which may include dialysate
rate, ultrafiltration rate, hemodialyzer
properties, patient residual intrinsic clearance,
and host volume status, first-dose PK
evaluations would be prudent in all critically
ill patients on CRRT who are administered
amikacin.
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